GPP
SIOX

Great Point Partners’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Great Point Partners’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-356,250
Closed -$15M – 47
2017
Q4 		$15M Buy
356,250
+355,040
+29,342% +$15.9M 2.56% 17
2017
Q3 		$67K Buy
+1,210
New +$204K 0.01% 37
2016
Q3 		– Sell
-3,125
Closed -$321K – 52
2016
Q2 		$321K Buy
+3,125
New +$312K 0.09% 34

Other funds holding SIOX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Great Point Partners's SIOX Position: Q1 2018 in Review

Great Point Partners sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2018, closing a stake of 356,250 shares — an estimated $15M sold.

Great Point Partners first reported a position in SIOX in Q2 2016 and held it in 3 quarters. The position peaked at $15M in Q4 2017. 81 funds tracked by Wall St. Rank hold SIOX as of Q1 2018.

  • Great Point Partners reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Great Point Partners sold 356,250 Sio Gene Therapies Inc. Common Stock shares in Q1 2018, an estimated $15M.
  • Great Point Partners first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2016 and held it in 3 quarters.
  • Great Point Partners's Sio Gene Therapies Inc. Common Stock position peaked at $15M in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2018.

Based on Great Point Partners's 13F filing for Q1 2018, filed 14 May 2018.